E. André-Garnier
French Institute of Health and Medical Research
4 Papers
2 Citations
E. André-Garnier is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Reverse transcriptase & Lopinavir. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study)
Bahia Amellal,Clotilde Allavena,E. André-Garnier,Virginie Ferré,Marc-Antoine Valantin,Jean-François Delfraissy,A. Lafeuillade,M. Bonmarchand,Vincent Calvez,François Raffi +9 more
TL;DR: Lopinavir/ritonavir+efavirenz did not affect mtDNA contents in PBMCs, compared to healthy donors and HIV-infected patients before and after exposure to NRTIs.
2
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Clotilde Allavena,C. Volteau,E. André-Garnier,Thomas Guimard,Nolwenn Hall,L. Khatchatourian,M. Morrier,Eric Billaud,A. Rodallec,V Reliquet,T. Jovelin,L. Le Guen,P. Perré,Matthieu Grégoire,François Raffi +14 more
TL;DR: The transient predator effect of nevirapine on dolutegravir had no clinical consequences after switching from ne virapine to doluteGravir, neither on safety nor maintenance of virologic suppression, and had no consequences on patient satisfaction.
1
Recours au test de résistance génotypique sur ADN VIH : Consensus Français de type DELPHI
E. André-Garnier,Laurence Bocket,Thomas Bourlet,Laurent Hocqueloux,Quentin Lepiller,A. Maillard,Sandrine Reigadas,B. Montes,Karl Stefic,A-G Marcelin +9 more
TL;DR: In this article , a consensus national de type DELPHI was initié dans l'objectif de faciliter l'homogénéisation des situations de recours and l'interprétation des résultats obtenus.
Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy.
Clotilde Allavena,A. Rodallec,A. Leplat,N. Hall,C. Luco,L. Le Guen,C. Bernaud,S. Bouchez,E. André-Garnier,David Boutoille,Virginie Ferré,François Raffi +11 more
TL;DR: This study supports that proviral DNA testing might be an informative tool before switching antiretrovirals in virologically suppressed patients with no history of virological failure, but the interpretation should be restricted to non-defective viruses.